
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
Click the title above to open the Pharmaceutical Technology November 2014 issue in an interactive PDF format.
about 12 years ago
New Era for Generic Drugsabout 12 years ago
Hype vs. Healthabout 12 years ago
Advances in Large-Scale Heterocyclic Synthesisabout 12 years ago
Steritest Symbio Pumps Increase Productivityabout 12 years ago
Tackling Drug Shortagesabout 12 years ago
Injecting Highly Viscous Drugsabout 12 years ago
Cleanroom Filtration System Minimizes Costsabout 12 years ago
Using Flow Sensors to Monitor Process System Healthabout 12 years ago
Parenterals, Particulates, and Quality by Design





